|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Active, not recruitingPhase 1/2IIT Investigator-Initiated Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CS01 in Patients With Locally Advanced or Metastatic Solid Tumors.
This is an investigator-initiated clinical trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of CS01 in patients with locally advanced or metastatic solid tumors.
100 Clinical Results associated with Zhongshan Constimulus Bio Co., Ltd
0 Patents (Medical) associated with Zhongshan Constimulus Bio Co., Ltd
100 Deals associated with Zhongshan Constimulus Bio Co., Ltd
100 Translational Medicine associated with Zhongshan Constimulus Bio Co., Ltd